https://www.nuaxia.com/ko/post/fda-clears-zeta-surgical-s-ai-powered-robotic-tms-navigation-system-for-treatment-resistant-depressi-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/roche-strengthens-breast-cancer-pipeline-with-490m-astex-partnership-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/distalmotion-expands-fda-clearance-for-dexter-robotic-system-in-gynaecology-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/medscape-general-surgeon-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/medscape-emergency-medicine-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/medscape-ophthalmologist-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/kelun-s-merck-partnered-adc-delivers-phase-iii-win-in-first-line-pd-l1-negative-lung-cancer-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/biogen-advances-tau-targeting-alzheimer-s-drug-diranersen-despite-phase-ii-dose-uncertainty-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/lupin-licenses-two-oncology-programmes-to-kaveri-therapeutics-for-an-82-2-equity-stake-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/forte-biosciences-reports-positive-phase-ib-results-for-fb102-vitiligo-treatment-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/fda-advisory-panel-recommends-four-peptides-for-503a-compounding-list-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/sanofi-s-sarclisa-escena-receives-fda-approval-as-first-oncology-drug-delivered-through-on-body-inje-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/ipsen-bets-up-to-1-75bn-on-kartos-to-strengthen-myelofibrosis-pipeline-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/medscape-cardiology-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/amga-2026-medical-group-physician-assistant-compensation-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/vedana-launches-with-46m-to-chase-the-next-wave-of-migraine-innovation-beyond-cgrp-therapies-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/kardigan-surges-on-400m-ipo-debut-as-cardiovascular-bets-draw-investor-momentum-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/vivani-spins-out-brain-computer-interface-business-through-nasdaq-reverse-merger-5 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/scribe-therapeutics-moves-toward-nasdaq-debut-as-crispr-pipeline-advances-into-clinic-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/amga-2026-medical-group-cardiology-compensation-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/fda-approves-accord-biopharma-s-ennumo-biosimilar-to-neulasta-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/donald-trump-announces-phased-tariffs-on-imported-generic-drugs-from-2028-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/medscape-pediatrician-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/campfield-launches-with-180m-to-rewire-pde4-strategy-in-ibd-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/european-commission-expands-approval-of-novartis-itvisma-for-broader-sma-patient-population-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/celea-therapeutics-secures-180m-to-advance-phase-iii-ipf-programme-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/ipsen-strengthens-rare-disease-pipeline-with-700m-memo-therapeutics-acquisition-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/biocytogen-and-whitehawk-partner-to-advance-next-generation-bispecific-adcs-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/astrazeneca-expands-china-partnerships-with-up-to-2-1bn-respiratory-drug-deal-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/medscape-internist-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/xrhealth-acquires-swing-therapeutics-to-expand-digital-chronic-pain-care-platform-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/thermo-fisher-and-arcturus-partner-to-advance-phase-iii-arct-032-cystic-fibrosis-programme-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/medscape-neurology-compensation-report-2026-5 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/insilico-medicine-and-china-medical-system-expand-ai-drug-discovery-partnership-with-177m-cns-deal-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/medscape-ob-gyn-compensation-report-2026-6 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/fda-approves-first-regulatory-t-cell-therapy-for-chronic-gvhd-prevention-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/fda-approves-celcuity-s-revtorpyk-for-pi3k-pathway-targeted-breast-cancer-treatment-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/fda-approves-subcutaneous-sarclisa-isatuximab-irfc-for-multiple-myeloma-treatment-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/bayer-secures-3bn-apollo-investment-in-contraceptives-business-as-pharma-strategy-evolves-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/interpreting-the-ddrb-2026-pay-award-what-the-workforce-data-is-really-signalling-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/medscape-dermatology-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/medscape-endocrinology-compensation-report-2026-6 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/merck-s-lipfendra-becomes-first-fda-approved-oral-pcsk9-inhibitor-for-high-cholesterol-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/uk-expands-wegovy-approval-to-include-mash-treatment-6 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/medscape-oncology-compensation-report-2026-6 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/amga-2026-medical-group-gastroenterologist-compensation-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/insilico-medicine-and-takeda-expand-ai-drug-discovery-collaboration-in-600m-partnership-6 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/fda-grants-orphan-drug-designation-to-aftx-201-for-bag3-associated-dilated-cardiomyopathy-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/fda-clears-ai-powered-diabetic-retinopathy-screening-software-from-ihealthscreen-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/amga-2026-medical-group-physician-compensation-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/astrazeneca-licences-sino-biopharmaceutical-s-tqc3721-respiratory-drug-in-potential-1-9bn-deal-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/fda-approves-trutakna-as-first-dual-baff-april-targeted-therapy-for-iga-nephropathy-5 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/medscape-psychiatrist-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/ottobock-acquires-fesia-technology-to-expand-neurorehabilitation-portfolio-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/crystalys-raises-130-million-to-advance-dotinurad-through-global-phase-3-gout-trials-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/novo-nordisk-explores-long-acting-semaglutide-implant-through-vivani-partnership-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/merck-kgaa-expands-life-sciences-business-with-11-3bn-bio-techne-acquisition-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/fda-approves-msd-s-keytruda-combinations-with-padcev-for-muscle-invasive-bladder-cancer-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/draig-therapeutics-raises-65m-to-advance-ampa-modulator-dt-101-for-depression-treatment-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/atacor-enrols-first-patient-in-pivotal-trial-of-extravascular-icd-system-for-cardiac-rhythm-manageme-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/fda-and-mhra-strengthen-transatlantic-regulatory-alignment-on-ai-devices-and-medicines-6 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/claria-medical-secures-fda-de-novo-clearance-for-hysterectomy-tissue-extraction-system-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/amga-2026-medical-group-orthopedic-surgeon-compensation-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/kalohexis-files-confidentially-for-ipo-to-advance-obesity-and-cachexia-pipeline-6 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/fda-clears-ihealthscreen-s-ai-diabetic-retinopathy-screening-software-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/jazz-amplifies-its-oncology-ambitions-with-2-4bn-abcellera-antibody-partnership-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/novartis-acquires-myricx-bio-in-up-to-1-5bn-deal-to-strengthen-adc-pipeline-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/medscape-family-medicine-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/vertex-acquires-crinetics-for-10b-to-expand-into-endocrinology-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/leo-cancer-care-raises-65m-to-expand-upright-radiotherapy-platform-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/medscape-urologist-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/uk-biotech-financing-hits-five-year-high-as-venture-capital-momentum-accelerates-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/nice-recommends-first-non-invasive-endometriosis-diagnostic-tools-for-nhs-use-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/astrazeneca-and-ionis-miss-primary-endpoint-in-phase-iii-attr-cm-trial-for-eplontersen-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/vb-spine-expands-surgical-navigation-portfolio-with-augmedics-ct-fluoro-technology-deal-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/astrazeneca-acquires-global-rights-to-dizal-s-zegfrovy-in-1-5bn-lung-cancer-deal-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/biogen-expands-immunology-pipeline-with-up-to-1b-acquisition-of-raythera-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/medscape-gastroenterologist-compensation-report-2026-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/lilly-to-acquire-ataibeckley-in-up-to-3-8bn-deal-to-expand-into-psychedelic-depression-therapies-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/fda-approves-lipfendra-as-the-first-oral-pcsk9-inhibitor-for-high-cholesterol-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/germany-passes-healthcare-cost-cutting-reforms-as-pharma-industry-warns-of-investment-impact-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/sanofi-and-lilly-back-advancell-s-315m-radiopharmaceutical-expansion-as-advc001-moves-towards-late-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/zymeworks-929m-bid-for-theravance-reshapes-its-revenue-base-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/fda-approves-johnson-johnson-s-dual-energy-catheter-ablation-platform-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/amga-2026-medical-group-nurse-practitioner-compensation-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_bb6ca2ff58ae4598b658e3f6e3f31626~mv2.jpg https://www.nuaxia.com/ko/post/boltz-expands-ai-drug-discovery-reach-with-takeda-collaboration-6 2026-07-24 https://static.wixstatic.com/media/8bf18b_816c8c31948e46088eb49f9e3ad95411~mv2.jpg https://www.nuaxia.com/ko/post/roche-secures-ce-mark-for-automated-blood-test-to-detect-latent-tuberculosis-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_66790bc48db343898a70f68c454ff576~mv2.jpg https://www.nuaxia.com/ko/post/merck-expands-ai-drug-discovery-push-with-510m-protillion-partnership-8 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg https://www.nuaxia.com/ko/post/puretech-backed-celea-raises-180m-to-challenge-established-ipf-treatments-7 2026-07-24 https://static.wixstatic.com/media/8bf18b_623dce35421b4d1e97b286d1383e36e3~mv2.jpg